Wealthcare Advisory Partners LLC Reduces Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Wealthcare Advisory Partners LLC reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.3% during the 4th quarter, Holdings Channel reports. The fund owned 3,077 shares of the pharmaceutical company’s stock after selling 41 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Vertex Pharmaceuticals were worth $1,252,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Arlington Trust Co LLC boosted its holdings in shares of Vertex Pharmaceuticals by 97.1% during the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 33 shares during the last quarter. Fortitude Family Office LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at $30,000. Baystate Wealth Management LLC increased its holdings in shares of Vertex Pharmaceuticals by 49.0% during the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock worth $31,000 after buying an additional 25 shares during the last quarter. OFI Invest Asset Management purchased a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth $25,000. Finally, NBC Securities Inc. acquired a new position in Vertex Pharmaceuticals in the third quarter valued at $34,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the sale, the executive vice president now owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the transaction, the executive vice president now directly owns 74,364 shares in the company, valued at approximately $31,250,727.36. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Stuart A. Arbuckle sold 4,295 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,804,930.80. Following the completion of the sale, the chief operating officer now owns 75,718 shares of the company’s stock, valued at approximately $31,819,732.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,381 shares of company stock worth $5,203,249. 0.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Wolfe Research started coverage on Vertex Pharmaceuticals in a report on Thursday, February 15th. They issued an “outperform” rating and a $515.00 price objective on the stock. Sanford C. Bernstein cut shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday, February 2nd. Canaccord Genuity Group reissued a “sell” rating and issued a $371.00 price objective on shares of Vertex Pharmaceuticals in a research report on Friday, April 12th. Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Tuesday. Finally, Evercore ISI raised Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price objective on the stock in a research report on Thursday, April 11th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $432.18.

Vertex Pharmaceuticals Trading Up 1.9 %

NASDAQ:VRTX opened at $410.24 on Wednesday. Vertex Pharmaceuticals Incorporated has a 12-month low of $320.01 and a 12-month high of $448.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78. The business has a 50 day simple moving average of $408.02 and a 200 day simple moving average of $400.75. The firm has a market capitalization of $106.03 billion, a P/E ratio of 29.53, a P/E/G ratio of 1.89 and a beta of 0.39.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share for the quarter, topping analysts’ consensus estimates of $3.66 by $1.10. The business had revenue of $2.69 billion for the quarter, compared to analysts’ expectations of $2.58 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.67 EPS. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.